{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "27107038",
  "DateCompleted": {
    "Year": "2017",
    "Month": "11",
    "Day": "03"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "03",
    "Day": "16"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2016",
        "Month": "04",
        "Day": "22"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1158/2159-8290.CD-16-0146"
    ],
    "Journal": {
      "ISSN": "2159-8290",
      "JournalIssue": {
        "Volume": "6",
        "Issue": "7",
        "PubDate": {
          "Year": "2016",
          "Month": "Jul"
        }
      },
      "Title": "Cancer discovery",
      "ISOAbbreviation": "Cancer Discov"
    },
    "ArticleTitle": "Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.",
    "Pagination": {
      "StartPage": "703",
      "EndPage": "713",
      "MedlinePgn": "703-13"
    },
    "Abstract": {
      "AbstractText": [
        "Personalized oncology aims to tailor therapy by targeting the unique genetic characteristics of a patient's tumor, whereas cancer immunotherapy focuses on activating the patient's immune system to control the tumor. The fusion of these ostensibly separate strategies has created a new dimension for personalized cancer immunotherapy. This entails the development of next-generation cancer vaccines that target neoantigens as well as the use of mutational signatures as predictive biomarkers for clinical response. The optimal use of immunotherapeutic agents will hinge on a robust understanding of the mutational profile of a cancer's genome that significantly dictates antitumor immunity and immunotherapeutic response.",
        "Cancer immunotherapy has provided substantial clinical benefit in a significant number of patients with advanced disease. However, the need for more precise immunotherapies and predictive biomarkers remains pressing. Recent progress in these areas has been promising and has created a framework for precision immune-oncology. Cancer Discov; 6(7); 703-13. \u00a92016 AACR."
      ],
      "CopyrightInformation": "\u00a92016 American Association for Cancer Research."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York."
          }
        ],
        "LastName": "Mandal",
        "ForeName": "Rajarsi",
        "Initials": "R"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. chant@mskcc.org."
          }
        ],
        "LastName": "Chan",
        "ForeName": "Timothy A",
        "Initials": "TA"
      }
    ],
    "GrantList": [
      {
        "GrantID": "R01 CA154767",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 CA177828",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "P50 CA172012",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "P30 CA008748",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "T32 CA009685",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review",
      "Research Support, N.I.H., Extramural"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Cancer Discov",
    "NlmUniqueID": "101561693",
    "ISSNLinking": "2159-8274"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antigens, Neoplasm"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Biomarkers, Tumor"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Cancer Vaccines"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "immunology"
      ],
      "DescriptorName": "Antigens, Neoplasm"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Biomarkers, Tumor"
    },
    {
      "QualifierName": [
        "immunology",
        "therapeutic use"
      ],
      "DescriptorName": "Cancer Vaccines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Genetic Predisposition to Disease"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Genomic Instability"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Genomics"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Immunomodulation"
    },
    {
      "QualifierName": [
        "adverse effects",
        "methods"
      ],
      "DescriptorName": "Immunotherapy"
    },
    {
      "QualifierName": [
        "methods",
        "trends"
      ],
      "DescriptorName": "Medical Oncology"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Molecular Targeted Therapy"
    },
    {
      "QualifierName": [
        "genetics",
        "immunology",
        "therapy",
        "virology"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [
        "adverse effects",
        "methods"
      ],
      "DescriptorName": "Precision Medicine"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    }
  ],
  "CoiStatement": "Disclosure of Potential Conflicts of Interest: T.A. Chan is a cofounder of Gritstone Oncology; No potential conflicts of interest for R.M."
}